Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

Nivolumab 25pembrolizumab 20Ipilimumab 15toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Cyclophosphamide 6Blood Specimen Collection 6trametinib 5fludarabine 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5durvalumab 4binimetinib 4aldesleukin 4Interleukin-2 4Injections 4Carboplatin 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Paclitaxel 3Introns 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Melanoma × Imatinib Mesylate × Clear all
NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Keio University

Phase 1/2 Unknown
22 enrolled
Dermatologic

Melanoma

NCT01782508 2013-02-04

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡